Dr. Ali Al-Ghamrawy, Chairman of the Egyptian Drug Authority, welcomed a delegation from Sun Pharma, headed by Mr. Andranil Sen, Regional Manager for the Middle East, North Africa, and Far East Markets, in the presence of Dr. Ali Omar, General Manager of Sun Pharma in Egypt and the Middle East. The meeting was held within the framework of strengthening mutual cooperation and supporting efforts to further develop Egypt’s pharmaceutical sector, reflecting the Authority’s commitment to expanding partnerships with leading global pharmaceutical companies.
Dr. Al-Ghamrawy emphasized that the meeting reflects the EDA’s commitment to strengthening strategic partnerships with leading global pharmaceutical manufacturers. He noted that supporting investment, facilitating technology transfer, and expanding local manufacturing capabilities represent key pillars of the Authority’s work, contributing to enhanced pharmaceutical security and ensuring the sustainable availability of essential pharmaceutical products in the Egyptian market.
For their part, the Sun Pharma delegation expressed their appreciation the EDA's role in fostering a supportive and attractive investment environment for the pharmaceutical industry. The delegation reaffirmed the company’s commitment to expanding its investments in Egypt through the launch of its new regional office and supporting initiatives aimed at localizing pharmaceutical manufacturing and transferring expertise and technology, thereby strengthening Egypt’s position as a regional hub for pharmaceutical industries.
During the meeting, the company highlighted the opening of its new regional office in the Arab Republic of Egypt, underscoring its commitment to expanding its investment presence in the Egyptian market and reinforcing Egypt’s role as a key regional hub serving markets across the region.
Furthermore, both sides discussed the company’s plans to support the localization of pharmaceutical industry in Egypt, with a focus on several priority therapeutic areas, particularly diabetes medications, antihypertensive, psychiatric and neurological pharmaceutical products. This aligns with the Egyptian state’s vision to strengthen local manufacturing, achieve pharmaceutical security, and ensure the sustainable availability of essential pharmaceutical products.
The meeting further reviewed the company’s contribution to supporting the availability of several pharmaceutical products included on the EDA’s priority list, reflecting its commitment to addressing the therapeutic needs of the Egyptian market and enhancing the stability of pharmaceutical supplies.
Additionally, both parties explored avenues for strengthening cooperation during the coming period in ways that support the development of Egypt’s pharmaceutical industry, enhance investment opportunities, facilitate technology transfer, and support the company’s regional expansion from the Egyptian market. These efforts contribute to advancing the Egyptian state's vision for developing the pharmaceutical sector and enhancing its competitiveness at both the regional and international levels.
This meeting comes within the framework of the EDA’s strategy to strengthen partnerships with global pharmaceutical companies and support the localization of pharmaceutical manufacturing and technology transfer. Such efforts contribute to enhancing pharmaceutical security, ensuring the availability of high-quality pharmaceutical products, and strengthening the competitiveness of Egypt’s pharmaceutical sector regionally and internationally.